Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well guadecitabine works in treating patients with
myelodysplastic syndromes that are at higher risk for becoming acute myeloid leukemia.
Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astex Pharmaceuticals National Cancer Institute (NCI)